CRISPR (CRSP) Therapeutics preparing to file clinical trial authorization application (CTA) in Europe by end of 2017 for CRISPR/Cas9 gene editing product to treat beta-thalassemia, a disorder causing hemoglobin deficiency

Source Link:

http://seekingalpha.com/pr/16768373-crispr-therapeutics-reports-fourth-quarter-full-year-2016-financial-results-provides-business